{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-254659","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.276506+00:00","generated_at":"2026-06-10T00:50:37.822111+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio starts Phase 2 GBM trial (INB-400) and completes Phase 1 dose escalation (INB-100)","bullets":["Enrollment open for Phase 2 trial of INB-400 in newly diagnosed GBM; plans ~40 patients in Arm A; primary endpoint 12-month OS.","Dose escalation phase of Phase 1 INB-100 trial in leukemia closed; clinical update expected at ASH Dec 9-12, 2023.","As of April 2023, 100% of evaluable patients (n=7) on INB-100 in durable complete remission; one patient progression-free >3 years.","First activated sites for INB-400: University of Louisville and Cleveland Clinic; INB-400 received FDA Orphan Drug Designation April 2023.","R&D Day held October 12, 2023; webcast available."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-254659","json":"https://secwatch.observer/filing/0001193125-23-254659.json","markdown":"https://secwatch.observer/filing/0001193125-23-254659.md","text":"https://secwatch.observer/filing/0001193125-23-254659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523254659/0001193125-23-254659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523254659/d535806d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:50:37.822111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}